Viral Hepatitis clinical trials at UCSF

1 research study open to eligible people

Tobevibart + Elebsiran in Chronic HDV Infection
open to eligible people ages 18-70
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
San Francisco, California and other locations

Last updated: August 7, 2025